Evidence map›Paper›PMID 38347415›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

ISOGlyP: O-Glycosylation Site Prediction Using Peptide Sequences and GALNTs.

Luisa Gracia Mazuca, Jonathon E Mohl

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
4.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Luisa Gracia MazucaThe University of Texas at El Paso, El Paso, TX, USA.
Jonathon E MohlThe University of Texas at El Paso, El Paso, TX, USA. jemohl@utep.edu.
The University of Texas at El Paso · US

Funding

MUCIN SITE SPECIFIC O-GLYCOSYLATIONR01CA078834 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERKEN, THOMAS A · 1999 to 2012
$3.4M
NCI NIH HHS R01 CA078834
6 · The paper itself

Abstract

Mucin-type O-glycosylation is one of the most common posttranslational modifications of proteins. The abnormal expression of various polypeptide GalNAc-transferases (GALNTs) which initiate and define sites of O-glycosylation is linked to many cancers and other diseases. Many current O-glycosylation prediction programs utilize O-glycoproteomics data obtained without using the transferase isoform(s) responsible for the glycosylation. With 20 different GALNTs in humans, having the ability to predict and interpret O-glycosylation sites in terms of specific GALNT isoforms is invaluable.To fill this gap, ISOGlyP (isoform-specific O-glycosylation prediction) has been developed. Using position-specific enhancement values generated based on GalNAc-T isoform-specific amino acid preferences, ISOGlyP predicts the propensity that a site would be glycosylated by a specific transferase. ISOGlyP gave an overall prediction accuracy of 70% against in vivo data, which is comparable to that of the NetOGlyc4.0 predictor. Additionally, ISOGlyP can identify the known effects of long- and short-range prior glycosylation and can generate potential peptide sequences selectively glycosylated by specific isoforms. ISOGlyP is freely available for use at https://ISOGlyP.utep.edu . The code is also available on GitHub ( https://github.com/jonmohl/ISOGlyP ).

Indexed as

N-AcetylgalactosaminyltransferasesPolypeptide N-acetylgalactosaminyltransferaseGlycosylationHumansPeptidesProtein IsoformsN-AcetylgalactosaminyltransferasesPeptidesPolypeptide N-acetylgalactosaminyltransferaseProtein IsoformsGalNAc-TGALNTMucin-type O-glycosylationO-Glycosylation predictionPTM prediction

Identifiers

PMID38347415
OpenAlexW4391783661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.